Showing 1 - 7 results of 7 for search 'Ana Slipicevic', query time: 0.03s Refine Results
  1. 1
    Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells

    Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells by Konstantin Byrgazov, Andrej Besse, Marianne Kraus, Ana Slipicevic, Fredrik Lehmann, Christoph Driessen, Lenka Besse

    Published 2021-07-01
    Get full text
    Article
  2. 2
    Evaluation of CHK1 activation in vulvar squamous cell carcinoma and its potential as a therapeutic target in vitro

    Evaluation of CHK1 activation in vulvar squamous cell carcinoma and its potential as a therapeutic target in vitro by Zhihui Wang, Mette S. Førsund, Claes G. Trope, Jahn M. Nesland, Ruth Holm, Ana Slipicevic

    Published 2018-08-01
    Get full text
    Article
  3. 3
    PB2071: SENSITIVITY OF MULTIPLE MYELOMA TO MELFLUFEN ASSOCIATES WITH DECREASED P53 ACTIVITY AND ENRICHMENT OF DNA DAMAGE REPAIR PATHWAY GENES

    PB2071: SENSITIVITY OF MULTIPLE MYELOMA TO MELFLUFEN ASSOCIATES WITH DECREASED P53 ACTIVITY AND ENRICHMENT OF DNA DAMAGE REPAIR PATHWAY GENES by Juho Miettinen, Philipp Sergeev, Sadiksha Adhikari, Maiju-Emilia Huppunen, Minna Suvela, Ana Slipicevic, Nina N Nupponen, Klara Acs, Fredrik Lehmann, Caroline Heckman

    Published 2023-08-01
    Get full text
    Article
  4. 4
    P598: DISRUPTION IN ONE-CARBON METABOLISM THROUGH MTHFD1 INHIBITION AS NOVEL THERAPEUTIC STRATEGY IN CHRONIC LYMPHOCYTIC LEUKEMIA

    P598: DISRUPTION IN ONE-CARBON METABOLISM THROUGH MTHFD1 INHIBITION AS NOVEL THERAPEUTIC STRATEGY IN CHRONIC LYMPHOCYTIC LEUKEMIA by Elodie Viry, Chloé Duculty, Nicole Kiweler, Coralie Pulido, Anais Oudin, Ana Slipicevic, Martin Henriksson, Johannes Meise, Thomas Helleday, Etienne Moussay, Jérôme Paggetti

    Published 2023-08-01
    Get full text
    Article
  5. 5
    Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug Melflufen

    Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug Melflufen by Arjen Gebraad, Roope Ohlsbom, Juho J. Miettinen, Promise Emeh, Toni-Karri Pakarinen, Mikko Manninen, Antti Eskelinen, Kirsi Kuismanen, Ana Slipicevic, Fredrik Lehmann, Nina N. Nupponen, Caroline A. Heckman, Susanna Miettinen

    Published 2022-05-01
    Get full text
    Article
  6. 6
    The one‐carbon metabolic enzyme MTHFD2 promotes resection and homologous recombination after ionizing radiation

    The one‐carbon metabolic enzyme MTHFD2 promotes resection and homologous recombination after ionizing radiation by Petra Marttila, Nadilly Bonagas, Christina Chalkiadaki, Hannah Stigsdotter, Korbinian Schelzig, Jianyu Shen, Crystal M. Farhat, Amber Hondema, Julian Albers, Elisée Wiita, Azita Rasti, Ulrika Warpman Berglund, Ana Slipicevic, Oliver Mortusewicz, Thomas Helleday

    Published 2024-09-01
    Get full text
    Article
  7. 7
    The Peptide–Drug Conjugate Melflufen Modulates the Unfolded Protein Response of Multiple Myeloma and Amyloidogenic Plasma Cells and Induces Cell Death

    The Peptide–Drug Conjugate Melflufen Modulates the Unfolded Protein Response of Multiple Myeloma and Amyloidogenic Plasma Cells and Induces Cell Death by Ken Flanagan, Romika Kumari, Juho J. Miettinen, Staci L. Haney, Michelle L. Varney, Jacob T. Williams, Muntasir M. Majumder, Minna Suvela, Ana Slipicevic, Fredrik Lehmann, Nina N. Nupponen, Sarah A. Holstein, Caroline A. Heckman

    Published 2022-03-01
    Get full text
    Article

Search Tools: